1. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J, 2013, 42(1): 239-251.
[2]
2. Trifirò G, de Ridder M, Sultana J, et al. Use of azithromycin and risk of ventricular arrhythmia. CMAJ, 2017, 189(15): E560-E568.
[3]
3. Santos S, Marin A, Serra-Batlles J, et al. Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation. Int J Chron Obstruct Pulmon Dis, 2016, 11: 515-525.
[4]
4. Mikura S, Wada H, Higaki M, et al. Erythromycin prevents the pulmonary inflammation induced by exposure to cigarette smoke. Transl Res, 2011, 158(1): 30-37.
[5]
5. Zhou Y, Tan X, Kuang W, et al. Erythromycin ameliorates cigarette-smoke-induced emphysema and inflammation in rats. Transl Res, 2012, 159(6): 464-472.
[6]
6. Bai J, Qiu SL, Zhong XN, et al. Erythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation. Mediators Inflamm, 2012, 2012: 410232.
[7]
7. He ZY, Li B, Yu L, et al. Suppression of oxidant-induced glutathione synthesis by erythromycin in human bronchial epithelial cells. Respiration, 2008, 75(2): 202-209.
[8]
8. Mercado N, To Y, Ito K, et al. Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-δ. J Pharmacol Exp Ther, 2011; 337:465-470.
[9]
9. Li M, Zhong XN, He ZY, et al. Effect of erythromycin on cigarette-induced histone deacetylase protein expression and nuclear factor-κB activity in human macrophages in vitro. Int Immunopharmacol, 2012, 12(4): 643-650.
[10]
10. Hodge S, Tran HB, Hamon R, et al. Nonantibiotic macrolides restore airway macrophage phagocytic function with potential anti-inflammatory effects in chronic lung diseases. Am J Physiol Lung Cell Mol Physiol, 2017, 312(5): L678-L687.
[11]
11. Sun XJ, Li ZH, Zhang Y, et al. Combination of erythromycin and dexamethasone improves corticosteroid sensitivity induced by CSE through inhibiting PI3K-δ/Akt pathway and increasing GR expression. Am J Physiol Lung Cell Mol Physiol, 2015, 309(2): L139-L146.
[12]
12. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med, 1998, 157(6 Pt 1): 1829-1832.
[13]
13. Nagai H, Shishido H, Yoneda R, et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration, 1991, 58(3-4): 145-149.
[14]
14. Nakamura H, Fujishima S, Inoue T, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J, 1999, 13(6): 1371-1379.
[15]
15. Kadota J, Mukae H, Ishii H, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med, 2003, 97(7): 844-850.
[16]
16. Li H, Zhou Y, Fan F, et al. Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases. Intern Med, 2011, 50(16): 1663-1669.
[17]
17. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med, 2008, 178(11): 1139-1147.
[18]
18. He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration, 2010, 80(6): 445-452.
[19]
19. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011, 365(8): 689-698.
[20]
20. Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med, 2014, 2(5): 361-368.
[21]
21. Kobayashi Y, Wada H, Rossios C, et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol, 2013, 169(5): 1024-1034.
[22]
22. Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest, 2015, 147(4): 894-942.
[23]
23. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet, 2012, 380(9842): 660-667.
[24]
25. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA, 2013, 309(12): 1260-1267.
[25]
26. Gao YH, Guan WJ, Xu G, et al. Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. PloS one, 2014, 9(3): e90047.
28. Cameron EJ, Chaudhuri R, Mair F, et al. et al. Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J, 2013, 42(5): 1412-1415.
[28]
29. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax, 2013, 68(4): 322-329.
[29]
30. Hahn DL, Grasmick M, Hetzel S, et al. Azithromycin for bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med, 2012, 25(4): 442-459.
[30]
31. Wong EH, Porter JD, Edwards MR, et al. The role of macrolides in asthma: current evidence and future directions. Lancet Respir Med, 2014, 2(8): 657-670.
[31]
32. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med, 2012, 366(20): 1881-1890.
[32]
33. No authors listed. In brief: FDA azithromycin warning. Med Lett Drugs Ther, 2013, 55(1413): 28.
[33]
34. Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA, 2014, 311(21): 2199-2208.
[34]
35. Svanstrom H, Pasternak B, Hviid A, et al. Use of azithromycin and death from cardiovascular causes. N Engl J Med, 2013, 368(18): 1704-1712.
[35]
36. Mosholder AD, Mathew J, Alexander JJ, et al. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med, 2013, 368(18): 1665-1668.
[36]
37. Justo D, Zeltser D, et al. Torsades de pointes induced by antibiotics. Eur J Intern Med, 2006, 17(4): 254-259.
[37]
38. Albert RK, Schuller JL, Network CCR, et al. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med, 2014, 189(10): 1173-1180.
[38]
24. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA, 2013, 309(12): 1251-1259.
